The Medical Letter on Drugs and Therapeutics
Indacaterol (Arcapta Neohaler) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009.

MAINTENANCE TREATMENT OF COPD — For patients with moderate to severe COPD, regular treatment with an inhaled long-acting bronchodilator such as the beta2-agonist salmeterol (Serevent) and/or the anticholinergic tiotropium (Spiriva HandiHaler) can relieve symptoms, improve lung function, and reduce the frequency of exacerbations. For patients with severe disease and frequent exacerbations, addition of an inhaled corticosteroid can be tried. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Indacaterol (Arcapta Neohaler) for COPD
Article code: 1389b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian